Biotech

All Articles

Pfizer takes $230M reached after axing failed DMD genetics therapy

.Pfizer's phase 3 Duchenne muscular dystrophy (DMD) gene treatment failure has blown a $230 thousand...

AC Immune sees 'spots' possible in Alzheimer's drug information

.After more than 20 years of service neurodegenerative health conditions, Swiss biotech hvac Immune ...

GSK drops ph. 2 HPV vaccine over absence of best-in-class potential

.GSK has broken up a period 2 human papillomavirus (HPV) vaccine from its pipeline after making a de...

OS Therapies refiles $6M IPO to cash HER2 medicine, preclinical ADCs

.Operating system Therapies will definitely provide on the NYSE American sell exchange today by mean...

ALX's waning CD47 reaction price delivers sell spiraling down

.ALX Oncology's phase 2 stomach cancer feedback fee has damaged. After finding its own CD47 blocker ...

Ionis centers eye illness coming from targets of Roche-partnered prospect after records disappoint

.Yet Another of Ionis Pharmaceuticals' key midphase readouts has actually disappointed requirements,...

Biogen's chief executive officer pointed out no unsafe sell 2023. He's ready to be bold

.While Biogen's pharma peers are searching for late-stage resources with little bit of threat, CEO C...

Instil refills pipe in $2B biobucks take care of ImmunOnco

.Instil Bio has actually been a biotech searching for a pipe after it scrapped its own lead resource...

Biogen ignores Denali Alzheimer's collab

.Biogen has restored liberties to an early Alzheimer's illness course to Denali Therapeutics, leavin...

Takeda taps brand new head of US oncology company-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our summary of significant leadership hirings, shootings...